CC BY-NC-ND 4.0 · Laryngorhinootologie 2021; 100(S 02): S130-S131
DOI: 10.1055/s-0041-1727987
Abstracts
Head-Neck-Oncology: Medical Tumor Therapy

Immunological Signature and Neoantigene Landscape of aggressive Salivary Gland Cancers

M Linxweiler
1   Univ. HNO-Klinik, Homburg/S.
,
V Makarov
2   Memorial Sloan Kettering Cancer Center, Human Oncology and Pathogenesis Program New York City United States
,
F Kuo
2   Memorial Sloan Kettering Cancer Center, Human Oncology and Pathogenesis Program New York City United States
,
N Katabi
3   Memorial Sloan Kettering Cancer Center, Department of Pathology New York City United States
,
D Chowell
2   Memorial Sloan Kettering Cancer Center, Human Oncology and Pathogenesis Program New York City United States
,
RJ. Wong
4   Memorial Sloan Kettering Cancer Center, Department of Head and Neck Surgery New York City United States
,
TA. Chan
5   Memorial Sloan Kettering Cancer Center, Department of Radiotherapy New York City United States
,
Luc G. T. Morris
4   Memorial Sloan Kettering Cancer Center, Department of Head and Neck Surgery New York City United States
› Author Affiliations
› Further Information
Also available at
 
 

    Introduction Salivary gland cancers (SGC) are rare but aggressive tumor diseases with a high rate of recurrence and distant metastasis resulting in a poor prognosis. In the few so far completed studies on checkpoint inhibitor therapy response rates have been low. A deeper understanding of relevant molecular alterations and immunological processes is urgently needed to improve the patients‘ prognosis as well as response to immunotherapy.

    MethodsTo analyze the immunological tumor signature and neoantigene landscape, RNA sequencing of 76 SGCs with three different histologies was performed: adenoidcystic carcinomas (ACC), myoepithelial carcinomas (MECA), and salivary duct carcinomas (SDC). Transcriptomic profile, tumor infiltrating immune cells as well as T cell activation and dysfunction scores have been analyzed. Additionally, whole exome sequencing (WES) was performed in 37 cases with an analysis of somatic mutations and tumor neoantigens.

    ResultsSDCs showed the strongest immune infiltration with the highest levels of T cell dysfunction and mutational load. On the contrary, ACCs showed an „immune-excluded“ phenotype with the highest levels of M2 macrophages and myeloid suppressor cells and a comparably low mutational load. MECAs showed a more heterogeneous pattern. For all three histologies, level of immune infiltration was strongly associated with the number of somatic mutations and neoantigenes.

    ConclusionThe results of our study provide new insights into the immunological signature and neoantigene landscape of SGCs and thereby can uncover immunological vulnerabilities of these difficult-to-treat cancers.

    Poster-PDF A-1020.pdf


    #

    Conflict of interest

    Der Erstautor gibt keinen Interessenskonflikt an.

    Address for correspondence

    Priv.-Doz. Dr. med. Linxweiler Maximilian
    Univ. HNO-Klinik
    Homburg/S.

    Publication History

    Article published online:
    13 May 2021

    © 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

    Georg Thieme Verlag KG
    Rüdigerstraße 14, 70469 Stuttgart, Germany